Avidity Biosciences Inc.

26.58
-1.52 (-5.41%)
At close: Apr 04, 2025, 3:59 PM
27.08
1.88%
After-hours: Apr 04, 2025, 04:45 PM EDT

Company Description

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies.

It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases.

The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage.

It also offers Lumizyme therapy for Pompe diseases.

Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Avidity Biosciences Inc.
Avidity Biosciences Inc. logo
Country United States
IPO Date Jun 12, 2020
Industry Biotechnology
Sector Healthcare
Employees 391
CEO Sarah Boyce

Contact Details

Address:
10578 Science Center Drive
San Diego, California
United States
Website https://www.aviditybiosciences.com

Stock Details

Ticker Symbol RNA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001599901
CUSIP Number 05370A108
ISIN Number US05370A1088
Employer ID 46-1336960
SIC Code 2834

Key Executives

Name Position
Sarah Boyce President, Chief Executive Officer & Director
John B. Moriarty Jr., ESQ., J.D. Chief Legal Officer & Corporate Secretary
Michael F. MacLean CPA Chief Financial Officer
Charles Calderaro III Chief Technical Officer
Dr. Frank P. McCormick Ph.D. Scientific Founder & Member of Scientific Advisory Board
Dr. Troy Edward Wilson J.D., Ph.D. Co-Founder & Independent Chairman
Dr. W. Michael F. Flanagan Ph.D. Chief Scientific Officer
Eric B. Mosbrooker Chief Commercial Officer
Prof. Mark E. Davis Ph.D. Scientific Founder, Member of Scientific Advisory Board and Member of Board of Managers
Teresa McCarthy Chief Human Resources Officer

Latest SEC Filings

Date Type Title
Apr 03, 2025 4 Filing
Mar 25, 2025 8-K Current Report
Mar 21, 2025 4 Filing
Mar 21, 2025 4 Filing
Mar 21, 2025 4 Filing
Mar 21, 2025 4 Filing
Mar 21, 2025 4 Filing
Mar 17, 2025 8-K Current Report
Mar 12, 2025 4 Filing
Mar 04, 2025 4 Filing